Microbot Medical to Review Recent Progress During Needham's Virtual Healthcare Conference

Medical to Review Recent Progress During Needham's Virtual Healthcare Conference

Mass., April 11, 2022 - Microbot Medical Inc. (Nasdaq: MBOT), announced it will be presenting at the Annual Needham Virtual

Healthcare Conference. Harel Gadot, Chairman, President and CEO will provide an overview of the Company and recent progress on Tuesday,

April 12th at 8:45am ET.

live and archived replays of the presentation may be accessed via the Investors' section, under Presentation + Resources'

of the Company's website at www.microbotmedical.com.

Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,

focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological platforms

provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for

patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available

at http://www.microbotmedical.com.

to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities

for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or

prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform

Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that

contain words such as "will," "believes," "plans," "anticipates," "expects"

and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and

uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of potential

products, including LIBERTY and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies,

uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting

from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information

on risks facing Microbot Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports

filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical

disclaims any intent or obligation to update these forward-looking statements, except as required by law.